Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.
You may also be interested in...
2016 witnessed a second straight year of decline in the number of new active substance launches worldwide, but trend data show that this hard measure of R&D productivity was still healthy compared with industry's performance during the first decade of the century.
As public companies prepare to present their financial reports for the first quarter of 2017, Scrip has gathered the stats on drug approvals for the first three months, as well as highlights of the biggest trial success and most disappointing clinical setbacks of this year so far.
The latest drug development news and highlights from our FDA Performance Tracker.